Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Klonopin anti-generic campaign includes letters to physicians, journal ads for perforated tabs.

Executive Summary

GENERIC CLONAZEPAM DOES NOT MEET KLONOPIN DISSOLUTION STANDARDS, ROCHE CLAIMS in a recent mailing to physicians and pharmacists. "Our tests of the Teva Pharmaceuticals brand of clonazepam tablets indicate that some batches of the product do not meet the dissolution standards that the FDA requires Klonopin tablets to meet," the cover letter asserts. Roche adds that "we have no evidence that the Teva product is not bioequivalent to Klonopin, but the disparity in dissolution standards is, in our view, unwarranted."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel